Results of a Five-Drug Combination Chemotherapy in Non-Small Cell Lung Cancer: A phase II trial

Authors

  • F. Marechal Institut Jean-Godinot, Medical Oncology Department, F-51056, Reims, Cedex, France
  • C. Incatasciato Institut Jean-Godinot, Medical Oncology Department, F-51056, Reims, Cedex, France
  • A. Cattan Institut Jean-Godinot, Medical Oncology Department, F-51056, Reims, Cedex, France

DOI:

https://doi.org/10.3109/02841868809093584

Keywords:

Chemotherapy, non-small cell lung cancer, 5-drug combination, phase II study

Abstract

Abstract

Twenty-six non-small lung cancer patients entered a phase II trial of a 5-drug combination chemotherapy. On day 1, patients received vinblastine, bleomycin, methotrexate, 5-FU, cisplan-tinum, leucovorin, and a similar sequence with an increased dosage was administered on day 6. Out of 22 fully evaluable patients we observed 1 CR and 7 PR. Hematological toxicity was significant, including 15 cases of neutropenia grade 4 and four grade 3, with one death during aplasia. Our results are disappointing but they are similar to most current reports on drug combinations in advanced non-small cell lung cancer. A better scheduling might improve the efficiency toxicity ratio.

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Marechal, F., Incatasciato, C., & Cattan, A. (1988). Results of a Five-Drug Combination Chemotherapy in Non-Small Cell Lung Cancer: A phase II trial. Acta Oncologica, 27(5), 537–539. https://doi.org/10.3109/02841868809093584

Issue

Vol. 27 No. 5 (1988): Acta Oncologica

Section

Articles